Gsa Capital Partners LLP Oragenics Inc Transaction History

Gsa Capital Partners LLP

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 11, 2022	SELL	$0.33 - $0.56 $135,611 - $230,128	-410,944 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$0.43 - $0.69 $106,205 - $170,423	246,990 Added 150.65%	410,944 $183,000
Q3 2021 Nov 12, 2021	BUY	$0.58 - $0.84 $95,093 - $137,721	163,954 New	163,954 $104,000
Q2 2021 Aug 05, 2021	SELL	$0.6 - $0.89 $29,260 - $43,402	-48,767 Closed	0 $0
Q1 2021 May 10, 2021	SELL	$0.52 - $1.52 $27,576 - $80,608	-53,032 Reduced 52.09%	48,767 $44,000
Q4 2020 Feb 03, 2021	BUY	$0.39 - $0.6 $19,654 - $30,237	50,395 Added 98.04%	101,799 $46,000
Q3 2020 Nov 06, 2020	BUY	$0.56 - $1.49 $28,786 - $76,591	51,404 New	51,404 $30,000

Ticker OGEN
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 116,395,000
Market Cap $40.7M
Description
Oragenics, Inc. develops antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus; and Terra CoV-2, an intramuscular vaccine candidate that provides immuni...

Get notified when there are updates to the investment portfolio of Gsa Capital Partners LLP, based on Form 13F filings with the SEC.

Stay updated on Gsa Capital Partners LLP with notifications on news.